Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals

American Journal of Medicine

Volumn 100, Issue 2, 1996, Pages 197-204

  Schectman, Gordon ^a,b   Hiatt, Jan ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Div of General Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; COLESTIPOL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG TOLERABILITY; FEMALE; GOUT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0030043107     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)89459-4     Document Type: Article

References (32)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol Levels. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3021.
2. Brown B, Albers J, Fisher L, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. NEJM. 1990;323:1337-1339,
3. Kane J, Malloy M, Ports T, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
4. Cashin HL, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013-3017.
5. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. NEJM. 1990;323:1112-1119.
6. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). NEJM. 1990;323:946-955.
7. Sempos C, Cleeman J, Carroll M, et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993;269:3009-3014.
8. Rubins H, Robins S, Collins D, et al. Distribution of lipids and lipoproteins in 9,000 men with coronary heart disease: Report from the VA-HDL Intervention Trial Screening Program. Am J Cardiol. In press.
9. Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am J Cardiol. 1993;71:759-765.
10. Schectman G, Hiatt J, Hartz A. Telephone contacts do not improve compliance to niacin or bile acid sequestrants. Ann Pharm, 1994;28:29-34.
11. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374,
12. Clofibrate and niacin in coronary heart disease. The Coronary Drug Project Research Group. JAMA. 1975;231:361-380.
13. Heudebert G, Ruiswyk JV, Hiatt J, Schectman G. Combination drug therapy for hypercholesterolemia: the trade-off between cost and simplicity. Arch Int Med. 1993;153:1828-1837.
14. Shear C, Franklin F, Stinnett S, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation. 1992;85:1293-1303.
15. The Simvastatin Pravastatin Study Group. A comparison of the efficacy and safety of simvastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol. 1993;71:1408-1414.
16. The Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol. 1993;71:810-815.
17. Allain C, Poon L, Chan C, et al. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
18. Megraw R, Dunn D, Biggs H. Manual and continuous-flow colorimetry of triacylglycerols by a fully enzymic method. Clin Chem. 1979;25:273-278.
19. 2. Clin Chem. 1983;29:2026-2030.
20. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative centrifuge. Clin Chem. 1972;18:499-502.
21. Brown B, Zhao X, Sacco D, Albers J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
22. Andrade S, Walker A, Gottlieb L, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? NEJM. 1995;332:1125-1131.
23. Wysowski K, Kennedy K, Gross T. Prescribed use of cholesterol-lowering drugs in the United States, 1978-1988. JAMA. 1990;263:2185-2188.
24. Sprecher D, Abrams J, Allen J, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med. 1994;120:537-543.
25. Denke M, Grundy S. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med. 1995;155: 393-399.
26. Schrott H, Stein E, Dujovne C, et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995;75:34-39.
27. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Card. 1988;62:285-345.
28. Reaven P, Witztum J. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 1988;109:597-598. Letter.
29. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 1994;73:339-345.
30. Jacobson T, Chinn M, Fromell G, et al. Fluvastatin, with and without niacin, for hypercholesterolemia. Am J Cardiol. 1994;74:149-154.
31. Fletcher S, Pappius E, Harper S. Measurement of medication compliance in a clinical setting. Comparison of three methods in patients prescribed digoxin. Arch Intern Med. 1979;139:635-638.
32. Gordis L, Markowitz M, Lilienfeld A. The inaccuracy of using interviews to estimate patient reliability in taking medications at home. Med Care. 1969;7:49-54.